[A22-105] Difelikefalin (pruritus) - Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2023
Project no.:
A22-105
Commission:
Commission awarded on 04.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
adult haemodialysis patients with moderate to severe chronic kidney disease–associated pruritus (CKD-aP)
Result of dossier assessment:
added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.